On the use of quantitative modeling to help understand prostate-specific antigen dynamics and other medical problems

American Journal of Clinical Pathology

Volumn 119, Issue 1, 2003, Pages 14-17

  Swanson, Kristin R ^a   True, Lawrence D ^a   Murray, J D ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; PROSTATE SPECIFIC ANTIGEN; PROTEINASE INHIBITOR; VIRUS PROTEIN; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

BRAIN TUMOR; EDITORIAL; GLIOMA; HALF LIFE TIME; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MATHEMATICAL MODEL; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE DISEASE; PROSTATECTOMY; TUMOR GROWTH; VIRUS INFECTION; BIOLOGICAL MODEL; BLOOD; CANCER INVASION; DRUG COMBINATION; MALE; NOTE; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROSTATE TUMOR;

ANTI-HIV AGENTS; BRAIN NEOPLASMS; DRUG THERAPY, COMBINATION; GLIOMA; HIV INFECTIONS; HUMANS; MALE; MODELS, BIOLOGICAL; NEOPLASM INVASIVENESS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 85047689060     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/AR0682JH8B1BG058     Document Type: Editorial

References (17)

1. Vollmer RT, Humphrey PA. Tumor volume in prostate cancer and serum prostate-specific antigen: analysis from a kinetic viewpoint. Am J Clin Pathol. 2003;119:80-89.
2. Murray JD. Mathematical Biology II. 3rd ed. New York, NY: Springer-Verlag; 2002.
3. Swanson KR, True L, Lin D, et al. A quantitative model for the dynamics of serum prostate specific antigen (PSA) as a marker for cancerous growth: an explanation for a medical anomaly. Am J Pathol. 2001;158:2195-2199.
4. Connor H, Woods HF, Ledingham JGG, et al. A model of L+ lactate metabolism in normal man. Ann Nutr Metab. 1982;26:254-263.
5. Connor H, Woods HF, Murray JD, et al. Utilisation of L+ lactate in patients with liver disease. Ann Nutr Metab. 1982;26:308-314.
6. Bjork T, Ljungberg B, Piironen T, et al. Rapid exponential elimination of free prostate-specific antigen contrasts the slow, capacity-limited elimination of PSA complexed to alphaantichymotrypsin from serum. Urology. 1998;51:58-62.
7. Haab F, Meulemans A, Boccon-Gibod L, et al. Clearance of serum PSA after open surgery for benign prostatic hypertrophy, radical cystectomy, and radical prostatectomy. Prostate. 1995;26:334-338.
8. Lein M, Brux B, Jung K, et al. Elimination of serum free and total prostate-specific antigen after radical retropubic prostatectomy. Eur J Clin Chem Clin Biochem. 1997;35:591-595.
9. Partin AW, Piantadosi S, Subong ENP, et al. Clearance rate of serum-free and total PSA following radical retropubic prostatectomy. Prostate Suppl. 1996;7:35-39.
10. Ravery V, Meulemans A, Boccon-Gibod L. Clearance of free and total serum PSA after prostatic surgery. Eur Urol. 1998;33:251-254.
11. Richardson T, Wojno KJ, Liang LW, et al. Half-life determination of serum free prostate-specific antigen following radical retropubic prostatectomy. Urology. 1996;48:40-43.
12. Semjonow A, Hamm M, Rathert P. Elimination kinetics of prostate-specific antigen serum and urine. Int J Biol Markers. 1994;9:15-20.
13. van Straalen JP, Bossens MMF, de Reijke TM, et al. Biological half-life of prostate-specific antigen after radical prostatectomy. Eur J Clin Chem Clin Biochem. 1994;32:53-55.
14. Ho DD, Neumann AU, Perelson AS, et al. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature. 1995;373:123-126.
15. Swanson KR, Alvord EC Jr, Murray JD. A quantitative model for differential motility of gliomas in grey and white matter. Cell Prolif. 2000;33:317-329.
16. Swanson KR, Alvord EC, Murray JD. Virtual brain tumors (gliomas) enhance the reality of medical imaging and highlight inadequacies of current therapy. Br J Cancer. 2002;86:14-18.
17. Murray JD, Cook J, Tyson R, et al. Spatial pattern formation in biology, I: dermal wound healing; II: bacterial patterns. J Franklin Inst. 1998;335B:303-332.